Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.

Pettitt, D; Goldstein, J L; McGuire, A; Schwartz, J S; Burke, T; Maniadakis, N

Pettitt, D; Goldstein, J L; McGuire, A; Schwartz, J S; Burke, T; Maniadakis, N.

Affiliation

Pettitt D; Outcomes Research, Pfizer Inc, New York, NY, USA.

Rheumatology (Oxford) ; 39 Suppl 2: 33-42; discussion 57-9, 2000 Dec.

Article in En | MEDLINE | ID: mdl-11276801

Subject(s)

Anti-Inflammatory Agents, Non-Steroidal/economics; Arthritis/economics; Economics, Pharmaceutical; Models, Economic; Sulfonamides/economics; Aged; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Arthritis/drug therapy; Celecoxib; Cost of Illness; Cost-Benefit Analysis; Humans; Middle Aged; Pyrazoles; Sulfonamides/therapeutic use; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Arthritis / Sulfonamides / Anti-Inflammatory Agents, Non-Steroidal / Economics, Pharmaceutical / Models, Economic Type of study: Health_economic_evaluation / Prognostic_studies Limits: Aged / Humans / Middle aged Language: En Journal: Rheumatology (Oxford) Year: 2000 Document type: Article

Search on Google

XML

PubMed Links